XML 29 R15.htm IDEA: XBRL DOCUMENT
v3.23.3

Segment Data | 12 Months Ended
--- | ---
Sep. 30, 2023
Segment Reporting [Abstract] |
Segment Data | Segment Data The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company’s segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Medical Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The primary customers served by Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers. Medical consists of the following organizational units: Medication Delivery Solutions; Medication Management Solutions; Pharmaceutical Systems. Life Sciences Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. In addition, Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; physicians’ office practices; retail pharmacies; academic and government institutions; and pharmaceutical and biotechnology companies. Life Sciences consists of the following organizational units: Integrated Diagnostic Solutions and Biosciences. Interventional Interventional provides vascular, urology, oncology and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by Interventional are hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via the segment's Homecare business. Interventional consists of the following organizational units: Surgery; Peripheral Intervention; Urology and Critical Care. Additional Segment Information Distribution of products is primarily through independent distribution channels, and directly to end-users by BD and independent sales representatives. No customer accounted for 10% or more of revenues in any of the three years presented. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income, which represents revenues reduced by product costs and operating expenses. The Company’s chief operating decision maker does not receive any asset information by business segment and, as such, the Company does not report asset information by business segment. The tables below reflect the Company’s revenues and operating income from continuing operations. Revenues and operating income from the former Diabetes Care business prior to its spin-off on April 1, 2022 are included in (Loss) Income from Discontinued Operations, Net of Tax. See Note 2 for further information. Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.
(Millions of dollars) | 2023 |  | 2022 |  | 2021
| United States |  | International |  | Total |  | United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions | $ | 2,519 |  |  | $ | 1,774 |  |  | $ | 4,293 |  |  | $ | 2,483 |  |  | $ | 1,825 |  |  | $ | 4,308 |  |  | $ | 2,253 |  |  | $ | 1,848 |  |  | $ | 4,101 |
Medication Management Solutions | 2,303 |  |  | 677 |  |  | 2,980 |  |  | 1,935 |  |  | 598 |  |  | 2,533 |  |  | 1,863 |  |  | 570 |  |  | 2,432 |
Pharmaceutical Systems | 666 |  |  | 1,563 |  |  | 2,229 |  |  | 533 |  |  | 1,468 |  |  | 2,001 |  |  | 428 |  |  | 1,400 |  |  | 1,828 |
Total segment revenues | $ | 5,488 |  |  | $ | 4,014 |  |  | $ | 9,502 |  |  | $ | 4,950 |  |  | $ | 3,891 |  |  | $ | 8,841 |  |  | $ | 4,544 |  |  | $ | 3,817 |  |  | $ | 8,361 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 1,774 |  |  | $ | 1,850 |  |  | $ | 3,624 |  |  | $ | 2,190 |  |  | $ | 1,995 |  |  | $ | 4,185 |  |  | $ | 2,477 |  |  | $ | 2,748 |  |  | $ | 5,225 |
Biosciences | 603 |  |  | 906 |  |  | 1,509 |  |  | 542 |  |  | 838 |  |  | 1,379 |  |  | 503 |  |  | 802 |  |  | 1,305 |
Total segment revenues | $ | 2,377 |  |  | $ | 2,756 |  |  | $ | 5,133 |  |  | $ | 2,732 |  |  | $ | 2,833 |  |  | $ | 5,564 |  |  | $ | 2,980 |  |  | $ | 3,550 |  |  | $ | 6,530 |
Interventional |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 1,159 |  |  | $ | 338 |  |  | $ | 1,497 |  |  | $ | 1,094 |  |  | $ | 306 |  |  | $ | 1,400 |  |  | $ | 1,023 |  |  | $ | 274 |  |  | $ | 1,296 |
Peripheral Intervention | 1,016 |  |  | 849 |  |  | 1,865 |  |  | 960 |  |  | 799 |  |  | 1,759 |  |  | 931 |  |  | 780 |  |  | 1,711 |
Urology and Critical Care | 1,073 |  |  | 301 |  |  | 1,374 |  |  | 986 |  |  | 319 |  |  | 1,305 |  |  | 894 |  |  | 338 |  |  | 1,232 |
Total segment revenues | $ | 3,247 |  |  | $ | 1,489 |  |  | $ | 4,736 |  |  | $ | 3,040 |  |  | $ | 1,424 |  |  | $ | 4,464 |  |  | $ | 2,847 |  |  | $ | 1,392 |  |  | $ | 4,239 |
Total Company revenues from continuing operations | $ | 11,113 |  |  | $ | 8,258 |  |  | $ | 19,372 |  |  | $ | 10,722 |  |  | $ | 8,148 |  |  | $ | 18,870 |  |  | $ | 10,371 |  |  | $ | 8,760 |  |  | $ | 19,131 |
The following tables provide a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes and segment information for both capital expenditures and depreciation and amortization.
(Millions of dollars) | 2023 |  | 2022 |  | 2021
Income from Continuing Operations Before Income Taxes |  |  |  |  |
Medical (a) (b) | $ | 1,967 |  |  | $ | 2,215 |  |  | $ | 1,985 |
Life Sciences | 1,585 |  |  | 1,710 |  |  | 2,391 |
Interventional | 1,217 |  |  | 1,081 |  |  | 933 |
Total Segment Operating Income | 4,769 |  |  | 5,006 |  |  | 5,311 |
Acquisition-related integration and restructuring expense | (313) |  |  | (173) |  |  | (179) |
Net interest expense | (403) |  |  | (382) |  |  | (460) |
Other unallocated items (c) | (2,391) |  |  | (2,668) |  |  | (2,981) |
Total Income from Continuing Operations Before Income Taxes | $ | 1,662 |  |  | $ | 1,783 |  |  | $ | 1,692 |
Capital Expenditures |  |  |  |  |
Medical | $ | 563 |  |  | $ | 602 |  |  | $ | 740 |
Life Sciences | 139 |  |  | 213 |  |  | 297 |
Interventional | 138 |  |  | 130 |  |  | 125 |
Corporate and All Other | 35 |  |  | 28 |  |  | 32 |
Total Capital Expenditures | $ | 874 |  |  | $ | 973 |  |  | $ | 1,194 |
Depreciation and Amortization |  |  |  |  |
Medical | $ | 1,199 |  |  | $ | 1,144 |  |  | $ | 1,097 |
Life Sciences | 277 |  |  | 283 |  |  | 352 |
Interventional | 799 |  |  | 789 |  |  | 769 |
Corporate and All Other | 13 |  |  | 13 |  |  | 12 |
Total Depreciation and Amortization | $ | 2,288 |  |  | $ | 2,229 |  |  | $ | 2,230 |
(a)The amounts in 2023, 2022 and 2021 include charges of $653 million, $72 million and $56 million, respectively, recorded to Cost of products sold, to adjust estimated future product remediation costs. (b)The amount in 2022 includes a charge of $54 million, recorded to Cost of products sold, to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit. (c)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount in 2023 includes a pre-tax gain recognized on the Company's sale of its Surgical Instrumentation platform of approximately $268 million, which is further discussed in Note 2. The amount in 2021 includes a pre-tax charge recorded to Other operating (income) expense, net, related to certain product liability matters of $361 million, as further discussed in Note 6. Geographic Information The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, and Australia and New Zealand); and Other, which is comprised of Latin America (which includes Mexico, Central America, the Caribbean and South America) and Canada. Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location. The table below shows revenues from continuing operations and long-lived assets of continuing operations by geographic area:
(Millions of dollars) | 2023 |  | 2022 |  | 2021
Revenues |  |  |  |  |
United States | $ | 11,113 |  |  | $ | 10,722 |  |  | $ | 10,371 |
EMEA | 4,244 |  |  | 4,043 |  |  | 4,548 |
Greater Asia | 2,913 |  |  | 3,047 |  |  | 3,069 |
Other | 1,102 |  |  | 1,058 |  |  | 1,142 |
| $ | 19,372 |  |  | $ | 18,870 |  |  | $ | 19,131 |
Long-Lived Assets |  |  |  |  |
United States | $ | 35,732 |  |  | $ | 36,617 |  |  | $ | 35,896 |
EMEA | 5,317 |  |  | 5,126 |  |  | 5,778 |
Greater Asia | 1,521 |  |  | 1,528 |  |  | 1,607 |
Other | 1,116 |  |  | 1,079 |  |  | 860 |
Corporate | 418 |  |  | 442 |  |  | 465 |
| $ | 44,104 |  |  | $ | 44,792 |  |  | $ | 44,606 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration